Strategic partnerships Potential sales opportunities exist through collaborations with major medical centers and research institutions, as evidenced by the Mayo Clinic collaboration to develop prolonged-release drug delivery for anti-cancer therapeutics. Engage academic medical centers and cancer research networks to explore co-development or licensing of INSB200 or related platforms.

Pain management focus Lead asset INSB200 targets prolonged, site-specific post-operative pain control. There is a clear channel for partnerships with ambulatory surgical centers, hospitals, and regional anesthesia programs seeking improved analgesia and reduced opioid utilization. Develop outreach around perioperative pain solutions and regional blocks.

Early-stage collaboration As a near-clinical-stage company with revenue in the lower tens of millions and ongoing investor and advisory activity, there is an opportunity to offer contract development and manufacturing, consulting, or technology licensing to equipment manufacturers, CROs, or contract suppliers aligned with injectable sustained-release platforms.

Strategic advisory leverage Recent expansion of Medical Advisory Board and engagement with experts signals openness to strategic input and collaborative R&D. Use this to position co-development discussions, thought leadership partnerships, and pilot studies with key clinical experts to validate delivery technology in targeted indications.

Diversified indications Beyond pain control, recent press indicates interest in prolonged-release drug delivery for anti-cancer therapeutics. This broadens cross-sell opportunities into oncology delivery platforms and may invite integration with device, formulation, or matrix partners looking to expand into sustained-release oncology applications.